One way our immune system protects us is by ridding our bodies of altered cells that could lead to cancer. But exactly how and when does our immune system sense cancer? How do tumors evolve to avoid being detected? And how can a better understanding of this process help develop better cancer treatments?
Memorial Sloan Kettering Cancer Center (MSK) computational biologist Benjamin Greenbaum, PhD, is looking for answers to these important questions. He is the co-director of Neoantigen Discovery for The Olayan Center for Cancer Vaccines at MSK, a hub for cancer vaccine discovery and innovation. The center’s computational efforts, which have also received funding from The Tow Foundation and are led by Dr. Greenbaum, are essential to designing effective cancer vaccines.
